Urology · Austin, TX
NPI
1871546283
Since 2006
Specialty
Urology
Code 208800000X
Group practices
0
Medicare group memberships
Hospitals
1
Hospital affiliations
608 Radam Ln
Austin, TX, 78745
Phone (512) 443-5988
Medicare paid, 2024
$464K
18,734 services
Medicare patients, 2024
854
Average age 76
Drug cost, 2024
$7.8M
5,787 prescriptions
Company payments, 2025
$916
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David L Phillips was code J0897 (injection, denosumab, 1 mg), 9,960 times for 38 patients. In total David L Phillips billed 18,734 services in 93 codes, and Medicare paid $464K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-11-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 9,960 | 38 | $20.39 | $203K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 907 | 591 | $11.66 | $11K |
| 99214 Office E&M - Established | Office | 786 | 485 | $86.82 | $68K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 684 | 120 | $46.90 | $32K |
| J1952 Leuprolide injectable, camcevi, 1 mg | Office | 546 | 13 | $43.20 | $24K |
| 81003 Clinical Chemistry | Office | 510 | 367 | $2.20 | $1,121 |
| 36415 Venipuncture Blood Collection | Office | 362 | 282 | $8.58 | $3,107 |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 305 | 97 | $36.21 | $11K |
| 99213 Office E&M - Established | Office | 227 | 192 | $59.52 | $14K |
| 99426 Chronic, Principal, and Transitional Care Management | Office | 171 | 34 | $43.48 | $7,435 |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 120 | 19 | $142.11 | $17K |
| 51798 Ultrasound - Nonspecific | Office | 119 | 107 | $8.61 | $1,025 |
| 96401 Chemotherapy Administration | Office | 67 | 16 | $52.62 | $3,526 |
| 52000 Cystourethroscopy | Office | 66 | 56 | $183.83 | $12K |
| 99204 Office E&M - New | Office | 59 | 59 | $113.53 | $6,698 |
By year: 2022 $510K for 19,322 services; 2023 $522K for 20,279 services; 2024 $464K for 18,734 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81003 Clinical Chemistry | 510 | 367 | $2.20 | $1,121 |
| 36415 Venipuncture Blood Collection | 362 | 282 | $8.58 | $3,107 |
| 81001 Clinical Chemistry | 14 | 14 | $3.11 | $43.54 |
Medicare prescription drug claims, 2024
In 2024, the drug David L Phillips prescribed most often to Medicare patients was Tamsulosin Hcl, with 1,031 prescriptions and refills. In total David L Phillips wrote 5,787 Medicare prescriptions that cost $7.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamsulosin Hcl Generic | 1,031 | 2,574 | 330 | $17K |
| Finasteride Generic | 790 | 2,025 | 234 | $10K |
| Orgovyx Relugolix | 587 | 604 | 75 | $1.6M |
| Myrbetriq Mirabegron | 381 | 570 | 108 | $247K |
| Prednisone Generic | 331 | 362 | 48 | $1,884 |
| Abiraterone Acetate Generic | 326 | 342 | 46 | $706K |
| Erleada Apalutamide | 262 | 266 | 36 | $3.5M |
| Gemtesa Vibegron | 153 | 220 | 37 | $103K |
| Cephalexin Generic | 153 | 233 | 87 | $1,344 |
| Dutasteride Generic | 148 | 397 | 44 | $4,412 |
| Methenamine Hippurate Generic | 141 | 198 | 35 | $9,221 |
| Oxybutynin Chloride Er Oxybutynin Chloride | 102 | 240 | 30 | $2,157 |
| Testosterone Cypionate Generic | 102 | 186 | 45 | $5,948 |
| Alfuzosin Hcl Er Alfuzosin Hcl | 91 | 245 | 29 | $1,929 |
| Testosterone Generic | 85 | 107 | 20 | $12K |
Brand drugs: 1,548 claims; generic drugs: 4,239 claims; opioid claims: 55.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David L Phillips $916 ($916 in general payments such as food, travel and fees) from 12 companies. The largest payer was Abbvie Inc. with $228.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 10 | $228 |
| Janssen Biotech, Inc. JNJ | 14 | $177 |
| Pfizer Inc. PFE | 6 | $127 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $101 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 3 | $56.94 |
| Sumitomo Pharma America, Inc. 4506.T | 2 | $45.83 |
| Accord Healthcare, Inc. | 2 | $44.15 |
| Olympus America Inc. | 1 | $38.53 |
| AstraZeneca Pharmaceuticals LP AZN | 1 | $35.06 |
| Merck Sharp & Dohme LLC MRK | 1 | $28.33 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.